1. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries Publication: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2017 Subject(s): Drug CostsInsurance, Pharmaceutical Services -- economicsMedicare Part B -- economicsProspective Payment SystemAbatacept -- economicsCertolizumab Pegol -- economicsCost SavingsInjections -- economicsSelf Care -- economicsHumansUnited StatesUnited States. Department of Health and Human Services.Centers for Medicare & Medicaid Services (U.S.)Healthcare common procedure coding system
